Adage Capital Partners Amends Sutro Biopharma Stake

TL;DR

**Adage Capital Partners updated their Sutro Biopharma stake, signaling a potential shift in institutional confidence.**

AI Summary

Adage Capital Partners, L.P. filed an amended SC 13G/A on February 7, 2024, indicating a change in their beneficial ownership of Sutro Biopharma, Inc. common stock as of December 31, 2023. While the filing doesn't specify the exact change in share count, it updates their position in Sutro Biopharma, whose stock trades under CUSIP 869367102. This matters to investors because significant changes in institutional ownership can signal confidence or concern about the company's future prospects.

Why It Matters

Changes in major institutional holdings can influence stock price and investor sentiment, as large investors often have deep insights into a company's value.

Risk Assessment

Risk Level: low — This filing is a routine update on institutional ownership and does not inherently present a direct risk to the company or its investors.

Analyst Insight

Investors should monitor subsequent filings from Adage Capital Partners, L.P. and other institutional investors to understand the evolving ownership landscape of Sutro Biopharma, Inc. and assess any significant shifts in sentiment.

Key Numbers

• 869367102 — CUSIP Number (identifies Sutro Biopharma, Inc. common stock)
• $0.001 — par value per share (par value of Sutro Biopharma, Inc. common stock)

Key Players & Entities

• Adage Capital Partners, L.P. (company) — the reporting person filing the SC 13G/A
• Sutro Biopharma, Inc. (company) — the issuer whose securities are being reported
• Delaware (place) — place of organization for Adage Capital Partners, L.P.
• December 31, 2023 (date) — date of event requiring the filing
• February 7, 2024 (date) — date the SC 13G/A was filed

Forward-Looking Statements

• Sutro Biopharma, Inc. may see increased scrutiny from investors regarding institutional ownership trends. (Sutro Biopharma, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• p24-0448sc13ga.htm (SC 13G/A) — 91KB
• 0000902664-24-001187.txt ( ) — 93KB

(a)

Item 1(a). NAME OF ISSUER The name of the issuer is Sutro Biopharma, Inc. (the “ Company ”).

(b)

Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES The Company’s principal executive offices are located at 111 Oyster Point Blvd, South San Francisco, California 94080.

(a)

Item 2(a). NAME OF PERSON FILING This statement is filed by: (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ ACP ”) with respect to the Common Stock directly owned by it; (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACPGP ”), as general partner of ACP with respect to the Common Stock directly owned by ACP; (iii) Adage Capital Management, L.P., a Delaware limited partnership (“ ACM ”), as the investment manager of ACP, with respect to the Common Stock directly owned by ACP; (iv) Robert Atchinson (“ Mr. Atchinson ”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACA ”), managing member of ACPGP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ ACPLLC ”), general partner of ACM, with respect to the Common Stock directly owned by ACP; and (v) Phillip Gross (“ Mr. Gross ”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the Common Stock directly owned by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the “ Reporting Persons .” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

(c)

Item 2(c). CITIZENSHIP ACP and ACM are limited partnerships organized under the laws of the State of Delaware. ACPGP is a limited liability company organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States. CUSIP No. 869367102 13G/A Page 8 of 10 Pages

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES Common Stock, par value $0.001 per share (the “ Common Stock ”).

(e)

Item 2(e). CUSIP NUMBER 869367102 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance company as defined in Section 3(a)(19) of the Act; (d) Investment company registered under Section 8 of the Investment Company Act of 1940; (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable . Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in this Schedule 13G/A is calculated based upon 60,953,204 shares of Common Stock outstanding as of November 8, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 13, 2023. CUSIP No. 869367102 13G/A Page 9 of 10 Pages Item 5. Not applicable. Item 6. Not applicable. Item 7.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATE: February 7, 2024 ADAGE CAPITAL PARTNERS, L.P. By: Adage Capital Partners GP, L.L.C., its general partner By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL PARTNERS GP, L.L.C. By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL MANAGEMENT, L.P. By: Adage Capital Partners LLC, its general partner /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member /s/ Robert Atchinson ROBERT ATCHINSON, individually /s/ Phillip Gross PHILLIP GROSS, individually

View Full Filing

View this SC 13G/A filing on SEC EDGAR